PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors

2018 ◽  
Vol 19 (2) ◽  
pp. 201-210 ◽  
Author(s):  
Yemarshet K. Gebreyohannes ◽  
Elizabeth A. Burton ◽  
Agnieszka Wozniak ◽  
Bernice Matusow ◽  
Gaston Habets ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Gastrointestinal Stromal Tumors ◽  
Kinase Inhibitor ◽  
Stromal Tumors ◽  
Xenograft Models

scholarly journals Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors

2019 ◽  
Vol 25 (24) ◽  
pp. 7287-7293 ◽  
Author(s):  
César Serrano ◽  
Alessandro Leal ◽  
Yanan Kuang ◽  
Jeffrey A. Morgan ◽  
Constance M. Barysauskas ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Phase I ◽  
Tyrosine Kinase Inhibitor ◽  
Gastrointestinal Stromal Tumors ◽  
Phase I Study ◽  
Kinase Inhibitor ◽  
Stromal Tumors

scholarly journals Recurrent Gastrointestinal Stromal Tumors in the Imatinib Mesylate Era: Treatment Strategies for an Incurable Disease

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Rebecca M. Platoff ◽  
William F. Morano ◽  
Luiz Marconcini ◽  
Nicholas DeLeo ◽  
Beth L. Mapow ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Imatinib Mesylate ◽  
Surgical Resection ◽  
Dose Escalation ◽  
Gastrointestinal Stromal Tumors ◽  
Kinase Inhibitor ◽  
Inhibitor Therapy ◽  
Stromal Tumors ◽  
Tyrosine Kinase Inhibitor Therapy

Introduction. Recurrence of gastrointestinal stromal tumors (GISTs) after surgical resection and imatinib mesylate (IM) adjuvant therapy poses a significant treatment challenge. We present the case of a patient who underwent surgical resection after recurrence and review the current literature regarding treatment. Case Presentation. A 58-year-old man with a large intra-abdominal jejunal GIST was treated with complete surgical resection followed by IM. The patient experienced disease recurrence 3.5 years later and underwent IM dose escalation and reresection. Conclusion. Current strategies to treat recurrent GIST include dose escalation, modifying adjuvant tyrosine kinase inhibitor therapy, and surgery. High-level evidence will be required to better define the combinatory roles of tyrosine kinase inhibitor therapy, guided by molecular profiling, and surgery in the management of recurrent GIST.

Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors

2010 ◽  
pp. NA-NA ◽  
Author(s):  
Minka van Dongen ◽  
Nigel D.L. Savage ◽  
Ekaterina S. Jordanova ◽  
Inge H. Briaire-de Bruijn ◽  
Kimberley V. Walburg ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Gastrointestinal Stromal Tumors ◽  
Kinase Inhibitor ◽  
Stromal Tumors ◽  
Anti Inflammatory

scholarly journals Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era

Cancer ◽  
2011 ◽  
Vol 118 (14) ◽  
pp. 3571-3578 ◽  
Author(s):  
Ryan S. Turley ◽  
Peter D. Peng ◽  
Srinevas K. Reddy ◽  
Andrew S. Barbas ◽  
David A. Geller ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Hepatic Resection ◽  
Tyrosine Kinase Inhibitor ◽  
Gastrointestinal Stromal Tumors ◽  
Kinase Inhibitor ◽  
Stromal Tumors
Sign in / Sign up

Export Citation Format

Share Document